Towards human cardiac new approach methodologies (NAMs) to evaluate the combination of repolarization prolonging and shortening drugs: a pilot study.

ABSTRACT:

Background and purpose

Nonclinical human cardiac new approach methodologies (NAMs), including human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) combined with multielectrode array (MEA) represent a highly predictive in vitro model for identifying drug-induced cardiac liabilities of individual drugs. Here, we extend the use of an in vitro cardiac NAM to evaluate the safety of a drug combination including moxifloxacin, an antibiotic, and QT prolonging drug, and cobicistat a pharmacokinetic booster shown to shorten repolarization in vitro.

Methods

To generate the in vitro cardiac NAM, MEA coupled with hiPSC-CMs were cultured for 7-8 days. Cells were treated with moxifloxacin and cobicistat individually or in combination and change

SUBMITTER: Geiger RM 

PROVIDER: S-EPMC12690487 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature